Clinical trial · Observational
Perioperative Hypogonadism in Men Undergoing Radical Cystoprostatectomy for Bladder Cancer
NCT03063125CI-TRIAL-00053059completedResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to examine the relationship between testosterone level changes around the time of radical cystectomy.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Cancer | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
| Low Testosterone Levels | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Bladder Cancer Patients
- description
- Patients with bladder cancer scheduled to undergo radical cystectomy (RC).
Primary outcomes (1)
- measure
- Number of Hypogonadism in Participants Based on Serum Testosterone 90 Days Post Radical
- timeFrame
- 90 days post-RC surgery
- description
- The count of participants with hypogonadism (the level of serum testosterone used as a threshold).
Secondary outcomes (3)
- measure
- The Number of Hypogonadism in Participants Based on Serum Testosterone 30 Days Post Radical Cystectomy
- timeFrame
- 30 days post-RC surgery
- description
- The count of participants with hypogonadism 30 days post radical cystectomy using the serum testosterone levels (the level of serum testosterone used as a threshold).
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of bladder cancer * Scheduled to undergo radical cystectomy Exclusion Criteria: * Evidence of advanced metastatic disease, * Undergoing cystectomy for non-bladder primary malignancy or bladder cancer type other than urothelial cell * History of breast or prostate cancer * Polycythemia, cardiovascular thromboembolism, untreated obstructive sleep apnea, uncontrolled heart failure, or acute coronary event in the past six months
References
Publications (0)
Data not yet available
No reference posted for this study.